Keppra XR was approved by the FDA based on data from an international clinical study of 158 epilepsy patients with partial-onset seizures who added 1,000mg of Keppra XR or placebo to their other epilepsy medications once daily. Keppra XR is also available in 500mg tablet strength.
According to UCB, Keppra XR extended-release tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in patients 16 years of age and older with epilepsy.